Business Wire: June 6, 2016 – TORONTO, Canada – Highland Therapeutics Inc.’s wholly owned subsidiary, Ironshore Pharmaceuticals and Development, Inc. (“Ironshore”), today announced positive clinical data from the second phase 3 pivotal trial of its investigational drug product, HLD-200 (delayed-…
